Indian pharmaceutical giant Cipla and Hyderabad-based CSIR-Indian Institute of Chemical Technology (IICT) has tied up to work on the development of antiviral drugs that can fight viral diseases including coronavirus. ICT has led up the task to develop active pharma ingredients (APIs) for the drug. When they are developed, it would be handed-over to Cipla, who would then produce the drugs.
Research on anti-viral drugs has been on throughout the world for long and many companies have evolved producing molecules having anti-viral properties. But due to lack of demand, these molecules were not broadly marketed, according to IICT sources.
IICT director S Chandrasekhar and principal scientist Prathama S Manikar said that Cipla chairman Yusuf Khwaja Hamied
has requested them to manufacture 3 compounds — Favipiravir, Remiesivir, and Bolaxivir. Cipla would look after analyses, approvals, and mass production of the drugs.
“Favipiravir and Remidesivir have already undergone clinical trials and hence we will not require much time to make them as the raw materials are promptly available. It could take about 06 to 10 weeks to make them. We had proactively started producing the molecules in our modern Kilo lab with scientists working in two shifts. The process to start Bolaxavir molecule will begin now,”
“We will make 100 gm of the compounds and test them on animals before approaching the regulatory authority for manufacturing the drug,” Chandrasekhar added.
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India.
Cipla was founded by Khwaja Abdul Hamied in 1935.
Cipla primarily produces medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control, depression, and other medical conditions.
Earlier, Cipla and IICT had made joined hands to make drugs for AIDS, cancer, etc.
Read more :